Actu / event2019-01-07T17:46:08+00:00

Nos actualités et évènements

Efficience des équipes et des organisations, la clé de croissance pour votre entreprise !

Efficience ou Efficacité : Serait-ce uniquement une question de sémantique ? L’Efficacité : Remplir le contrat, satisfaire le client, atteindre l’objectif. L’Efficacité ne préjuge en rien de l’ensemble des ressources mobilisées pour obtenir ce résultat. L’Efficience : Mesurer [...]

25 février 2019|Actualités|

Pour aller plus loin …

  • HKTDC Hong Kong International Medical and Healthcare Fair Presents Leading-Edge Medical Products and Unveils Trends 18 mars 2019
    Monday, March 18th 2019 at 3:00am UTC HONG KONG–(BUSINESS WIRE)– Hong Kong, The HKTDC Hong Kong International Medical and Healthcare Fair (Medical Fair) will take place at the Hong Kong Convention and Exhibition Centre (HKCEC) from 14 to 16 May. Organised by the Hong Kong Trade Development Council (HKTDC) and co-organised by the Hong Kong […]
  • AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention 17 mars 2019
    Sunday, March 17th 2019 at 3:45pm UTC AUGUSTUS is the largest trial in this high-risk patient population requiring both anticoagulant and antiplatelet therapies PRINCETON, N.J. & NEW YORK–(BUSINESS WIRE)– The Bristol-Myers Squibb–Pfizer Alliance today announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis® (apixaban) versus vitamin K antagonists (VKAs) in patients with non-valvular atrial […]
  • Clovis Oncology to Highlight Rubraca® (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress 16 mars 2019
    Saturday, March 16th 2019 at 4:45pm UTC Exploratory analyses of ARIEL3 Rubraca data in recurrent ovarian cancer presented in oral plenary and poster sessions Maintenance treatment with Rubraca improved median progression-free survival (PFS) and reduced the risk of progression vs placebo regardless of age subgroup Maintenance treatment with Rubraca significantly improved PFS and reduced the […]
  • Apple Heart Study Demonstrates Ability of Wearable Technology to Detect Atrial Fibrillation 16 mars 2019
    Saturday, March 16th 2019 at 2:00pm UTC Stanford researchers presented preliminary findings from a virtual study that enrolled more than 400,000 participants. PALO ALTO, Calif.–(BUSINESS WIRE)– Researchers from the Stanford University School of Medicine today presented preliminary results of the Apple Heart Study, an unprecedented virtual study with over 400,000 enrolled participants. The researchers reported […]
  • Myomo Makes NYSE American Section 610(b) Public Announcement 15 mars 2019
    Friday, March 15th 2019 at 8:05pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended […]
  • Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial 15 mars 2019
    Friday, March 15th 2019 at 8:17pm UTC TAMPA, Fla.–(BUSINESS WIRE)– Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces the enrollment of the 60th patient in its Phase 2 double blind, placebo controlled clinical trial of AG013 (NCT03234465). AG013 is […]
  • Pulse Biosciences Grants Equity Incentive Awards to New Employees 15 mars 2019
    Friday, March 15th 2019 at 8:33pm UTC HAYWARD, Calif.–(BUSINESS WIRE)– Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ System, announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 61,000 shares of […]
  • Precision Medicine for Pediatric Cancer 15 mars 2019
    Friday, March 15th 2019 at 6:57pm UTC Considering the implications for diagnosis and treatment LOS ANGELES–(BUSINESS WIRE)– Research performed over the last several decades has led to an increased understanding of the genetics of cancer. The clinical application of this knowledge for pediatric cancer has lagged behind studies performed for adults. In a perspectives article […]
  • Inova Health System and Roswell Park Comprehensive Cancer Center Join KIYATEC Clinical Trial to Predict Patient Response to Cancer Drugs Prior to Treatment 15 mars 2019
    Friday, March 15th 2019 at 5:02pm UTC GREENVILLE, SC.–(BUSINESS WIRE)– KIYATEC, Inc. today announced that the company has opened Inova Health System (Inova) and Roswell Park Comprehensive Care Center as sites for its U.S. clinical study, 3D-PREDICT, to validate the company’s test as a patient-specific predictor of response to cancer therapies in ovarian, glioblastoma (GBM) […]
  • Enigma Biomedical Group Signs License Agreement with Merck for Novel MK-6884 Imaging Agent 15 mars 2019
    Friday, March 15th 2019 at 5:58pm UTC TORONTO–(BUSINESS WIRE)– Enigma Biomedical Group (EBG) today announced an exclusive license agreement with Merck, known as MSD outside the US and Canada, for the global development and commercialization of MK-6884, an early stage investigational imaging agent developed by Merck for use in Positron Emission Tomography (PET) scans to […]

de votre projet !

Un projet concret à booster

Besoin de conseils pour valider votre réflexion stratégique ou opérationnelle

Contactez-nous !

Articles récents

Contact Info

6, rue Alfred de Musset - 94800 Villejuif

Phone: +33 9 86 56 14 74

Mobile: +33 6 85 67 46 91